Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 07, 2024

Vaccine Safety and Immunogenicity in Patients With MS Treated With Natalizumab

JAMA Network Open

 

Additional Info

JAMA Network Open
Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab
JAMA Netw Open 2024 Apr 01;7(4)e246345, R Carvajal, A Zabalza, P Carbonell-Mirabent, X Martínez-Gómez, J Esperalba, A Pappolla, A Rando, A Cobo-Calvo, C Tur, M Rodriguez, J Río, M Comabella, J Castilló, JÁ Rodrigo-Pendás, N Braga, N Mongay-Ochoa, C Guío-Sánchez, Á Vidal-Jordana, G Arrambide, B Rodríguez-Acevedo, L Midaglia, B Borras-Bermejo, I Galán, J Sastre-Garriga, X Montalban, S Otero-Romero, M Tintoré

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading